Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.
An alpha-glucosidehydrolase inhibitor (acarbose; BAY g 5421) taken with food was compared with dummy tablets in seven insulin-treated diabetic patients over eight-hour periods that included breakfast, lunch, and two snacks. Acarbose diminished the postprandial increases in blood glucose, lactate, and pyruvate concentrations and may therefore be of value in the management of insulin-dependent diabetes.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003511:Cyclohexanols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005502:Food; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007773:Lactates / Q000097:blood; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000494:pharmacology*; D011773:Pyruvates / Q000097:blood; D014312:Trisaccharides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D003511:Cyclohexanols; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D007773:Lactates; D009844:Oligosaccharides; D011773:Pyruvates; D014312:Trisaccharides; D005959:Glucosidases